Retatrutide for Obesity: Complete Treatment Guide

Obesity affects over 42% of American adults and is now recognized as a chronic, relapsing disease driven by complex hormonal and neurological mechanisms -- not simply a lack of willpower. The arrival of GLP-1 receptor agonists like semaglutide and tirzepatide transformed obesity treatment, but retatrutide may push the boundaries even further. In the landmark Phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine (2023), retatrutide demonstrated weight loss results that rivaled bariatric surgery, all through a once-weekly injection.

What Is Retatrutide and How Does It Treat Obesity?

Retatrutide (also known as LY3437943) is a triple-hormone receptor agonist developed by Eli Lilly. Unlike semaglutide, which activates only the GLP-1 receptor, or tirzepatide, which activates both GLP-1 and GIP receptors, retatrutide activates three receptors simultaneously:

• GLP-1 receptor: Reduces appetite, slows gastric emptying, and improves insulin secretion -- the same mechanism behind semaglutide and the weight loss component of tirzepatide.
• GIP receptor: Enhances insulin sensitivity and may amplify GLP-1-driven appetite suppression, as seen with tirzepatide.
• Glucagon receptor: The differentiator. Glucagon activation increases energy expenditure, promotes fat burning (particularly liver and visceral fat), and boosts metabolic rate -- counteracting the metabolic slowdown that typically accompanies weight loss.

This three-pronged approach addresses obesity from multiple angles: suppressing appetite, improving metabolic efficiency, and directly increasing caloric expenditure. The glucagon receptor component is what sets retatrutide apart and likely explains its superior weight loss results.

Phase 2 Clinical Trial Results for Obesity

The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Participants were randomized to various retatrutide doses or placebo for 48 weeks.

These results are remarkable for several reasons. The weight loss curve had not plateaued at 48 weeks, suggesting that longer treatment could produce even greater weight loss. Nearly all participants at the highest dose achieved clinically meaningful weight loss (defined as 5% or more). And the results approached what is typically seen only with bariatric surgery.

How Retatrutide Compares to Current Obesity Treatments

To put retatrutide's obesity results in context, it helps to compare across the current treatment landscape:

While semaglutide and tirzepatide already represent major advances over older obesity medications, retatrutide pushes into territory previously reserved for surgical intervention. For patients with severe obesity who are reluctant or ineligible for surgery, this is particularly meaningful. Learn more in our detailed three-way comparison.

Who Is Eligible for Retatrutide Obesity Treatment?

Based on Phase 2 trial inclusion criteria and standard obesity medicine practice, likely candidates for retatrutide include:

• Adults with BMI 30 or higher -- clinical obesity by standard definition
• Adults with BMI 27-29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Patients who have not responded adequately to semaglutide or tirzepatide -- retatrutide's additional glucagon mechanism may succeed where dual agonists have not
• Patients seeking an alternative to bariatric surgery -- retatrutide offers surgery-like weight loss without the surgical risks

The ideal candidate profile includes individuals committed to long-term lifestyle changes, as medication-induced weight loss is best maintained with ongoing healthy habits.

Retatrutide Dosing for Obesity

In clinical trials, retatrutide was titrated slowly to minimize side effects. The dosing schedule typically followed a pattern of starting at a low dose and increasing every four weeks:

• Weeks 1-4: Starting dose (typically 1-2 mg weekly)
• Weeks 5-8: Intermediate escalation
• Weeks 9-12: Further escalation
• Week 12+: Target maintenance dose (up to 12 mg weekly)

This gradual titration is critical for tolerability. Patients who escalate too quickly experience significantly more nausea, vomiting, and diarrhea. The management of GI side effects is an important component of successful treatment.

Safety and Side Effects in Obesity Treatment

The Phase 2 trial's safety profile was generally consistent with other GLP-1-based medications. The most common side effects were gastrointestinal and typically manageable:

• Nausea: 20-25% of participants (usually mild and transient)
• Diarrhea: 15-20%
• Vomiting: 8-12%
• Constipation: 10-15%
• Decreased appetite: Common, but considered a therapeutic effect

Serious adverse events were uncommon. However, as with all GLP-1 medications, retatrutide should not be used by patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Read our complete retatrutide side effects guide for detailed information.

Why Start Obesity Treatment Now?

While retatrutide's obesity data is exciting, waiting for its approval means delaying treatment for a progressive disease. Obesity causes cumulative damage to joints, the cardiovascular system, and metabolic health. Every month of effective treatment prevents further harm. Both compounded semaglutide ($99/mo) and compounded tirzepatide ($125/mo) are available today and produce significant, clinically meaningful weight loss.